Estrogen Receptor Antagonist class drugs
7 results
Faslodex (fulvestrant)
(Fulvestrant)AstraZeneca Pharmaceuticals LP
Usage: FASLODEX is indicated for the treatment of HR-positive, HER2-negative advanced breast cancer in postmenopausal women, either as monotherapy for those not previously treated with endocrine therapy or after progression on such treatment. It can also be used in combination with ribociclib, palbociclib, or abemaciclib.
Fulvestrant (fulvestrant)
(Fulvestrant)Alembic Pharmaceuticals Inc.
Usage: Fulvestrant injection is indicated for treating hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women, as monotherapy or in combination with ribociclib, palbociclib, or abemaciclib, either as initial therapy or after disease progression on endocrine therapy.
Fulvestrant (fulvestrant)
(fulvestrant)Xiromed, LLC
Usage: Fulvestrant injection is indicated for treating HR-positive, HER2-negative advanced breast cancer in postmenopausal women. It can be used alone in those not previously treated with endocrine therapy or with disease progression after treatment. It is also indicated in combination with ribociclib, palbociclib, or abemaciclib.
Fulvestrant (fulvestrant)
(Fulvestrant)BluePoint Laboratories.
Usage: Fulvestrant injection is indicated for treating hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women. It is used as monotherapy for those not previously treated with endocrine therapy or with disease progression after such therapy, and in combination with ribociclib, palbociclib, or abemaciclib.
Fulvestrant (fulvestrant)
(Fulvestrant)Hikma Pharmaceuticals USA Inc.
Usage: Fulvestrant injection is indicated for treating HR-positive, HER2-negative advanced breast cancer in postmenopausal women, both as monotherapy and in combination with ribociclib, palbociclib, or abemaciclib, depending on previous treatments and disease progression.
Fulvestrant (fulvestrant)
(fulvestrant)Zydus Lifesciences Limited
Orserdu (elacestrant)
(Elacestrant)Stemline Therapeutics, Inc.
Usage: ORSERDU is indicated for treating postmenopausal women or adult men with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy.